Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prevalence of Function-Limiting Late Effects in Hodgkin Lymphoma Survivors

Nabela Enam, Kathy Chou, Michael D. Stubblefield
doi: https://doi.org/10.1101/2020.10.02.20202408
Nabela Enam
1Department of Physical Medicine & Rehabilitation, Rutgers New Jersey Medical School, Newark, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: enamn@upmc.edu
Kathy Chou
1Department of Physical Medicine & Rehabilitation, Rutgers New Jersey Medical School, Newark, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Stubblefield
2Kessler Institute for Rehabilitation, West Orange, NJ, USA; Department of Physical Medicine & Rehabilitation, Rutgers New Jersey Medical School, Newark, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective To define the prevalence of neuromuscular, musculoskeletal, pain, visceral, oncologic and other late effects impacting function and quality of life in Hodgkin lymphoma(HL) survivors presenting to an outpatient cancer rehabilitation clinic.

Design A retrospective cohort analysis.

Setting Outpatient cancer rehabilitation clinic.

Participants One hundred consecutive HL survivors.

Interventions None.

Main Outcome Measures The prevalence of neuromuscular, musculoskeletal, pain, visceral, oncologic and other late effects contributing to functional impairment and disability in HL survivors.

Results Among the 100 HL survivors, 43% received chemotherapy, 94% radiation therapy, and 38% a combination of chemotherapy and radiation for initial treatment. Nearly all HL survivors were diagnosed with myelopathy (83%), radiculo-plexopathy (93%), mononeuropathy (95%) and localized myopathy (93%). Musculoskeletal sequelae were extremely common and included dropped head syndrome (83%), cervicalgia (79%), shoulder girdle dysfunction (73%), and dysphagia (42%). Visceral disorders were also common and included cardiovascular (70%), pulmonary (44%), endocrine (63%), gastrointestinal (29%), and genitourinary (11%) dysfunction. Lymphedema affected 21% of survivors and 30% had a history of a secondary malignancy. Pain (71%), fatigue (45%), and dyspnea (43%) were major function-limiting impairments. Nearly all (95%) of survivors were referred to at least one therapy discipline including physical therapy, occupational therapy, speech and language pathology and/or lymphedema therapy.

Conclusion Neuromuscular, musculoskeletal, pain, visceral, oncologic and other late effectsare extremely common in HL survivors seeking physiatric evaluation. Multiple function-limiting disorders can co-exist in HL survivors with the potential to severely compromise function and quality of life. Safe and effective rehabilitation may depend on the physiatrist’s ability to identify, evaluate and manage the multitude of complex and often interrelated functional late effects seen in HL survivors.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

There was no funding required to support the work presented.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Institutional Review Board at the Kessler Foundation.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Reprints: Not available

  • Conflicts of Interest: None

  • Clinical Trial Registration Number: N/A

Data Availability

Data for 100 sequential patients previously diagnosed and treated for late effects of Hodgkin Lymphoma was available and included in the study

  • List of Abbreviations

    ADL
    activities of daily living
    CMT
    combined modality therapy
    DHS
    dropped head syndrome
    HL
    Hodgkin lymphoma
    OT
    occupational therapy
    PT
    physical therapy
    RT
    radiation therapy
    SGD
    shoulder girdle dysfunction
    SLP
    speech and language pathology therapy
    QOL
    quality of life
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted October 05, 2020.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Prevalence of Function-Limiting Late Effects in Hodgkin Lymphoma Survivors
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Prevalence of Function-Limiting Late Effects in Hodgkin Lymphoma Survivors
    Nabela Enam, Kathy Chou, Michael D. Stubblefield
    medRxiv 2020.10.02.20202408; doi: https://doi.org/10.1101/2020.10.02.20202408
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Prevalence of Function-Limiting Late Effects in Hodgkin Lymphoma Survivors
    Nabela Enam, Kathy Chou, Michael D. Stubblefield
    medRxiv 2020.10.02.20202408; doi: https://doi.org/10.1101/2020.10.02.20202408

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Rehabilitation Medicine and Physical Therapy
    Subject Areas
    All Articles
    • Addiction Medicine (227)
    • Allergy and Immunology (500)
    • Anesthesia (110)
    • Cardiovascular Medicine (1226)
    • Dentistry and Oral Medicine (205)
    • Dermatology (147)
    • Emergency Medicine (282)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (527)
    • Epidemiology (9996)
    • Forensic Medicine (5)
    • Gastroenterology (497)
    • Genetic and Genomic Medicine (2440)
    • Geriatric Medicine (236)
    • Health Economics (479)
    • Health Informatics (1634)
    • Health Policy (750)
    • Health Systems and Quality Improvement (633)
    • Hematology (247)
    • HIV/AIDS (530)
    • Infectious Diseases (except HIV/AIDS) (11851)
    • Intensive Care and Critical Care Medicine (625)
    • Medical Education (251)
    • Medical Ethics (74)
    • Nephrology (267)
    • Neurology (2271)
    • Nursing (139)
    • Nutrition (349)
    • Obstetrics and Gynecology (451)
    • Occupational and Environmental Health (532)
    • Oncology (1243)
    • Ophthalmology (375)
    • Orthopedics (133)
    • Otolaryngology (226)
    • Pain Medicine (154)
    • Palliative Medicine (50)
    • Pathology (324)
    • Pediatrics (728)
    • Pharmacology and Therapeutics (311)
    • Primary Care Research (281)
    • Psychiatry and Clinical Psychology (2278)
    • Public and Global Health (4820)
    • Radiology and Imaging (833)
    • Rehabilitation Medicine and Physical Therapy (487)
    • Respiratory Medicine (650)
    • Rheumatology (283)
    • Sexual and Reproductive Health (237)
    • Sports Medicine (224)
    • Surgery (266)
    • Toxicology (44)
    • Transplantation (123)
    • Urology (99)